VHH Antibody Discovery
Fast, Customised and Built for Scientists
Custom VHH Antibody discovery, delivered with speed, precision, and partnership – powered by the world’s largest synthetic VHH libraries and proprietary CIS Display™ technology.
Antibody discovery - Fast, Customised and Built for Scientists
At Isogenica, we work as a specialized extension of your team – open, agile, and grounded in science. From high-throughput screening to custom VHH engineering, our approach accelerates timelines, strengthens IP, and reduces early-stage risk. Whether you’re targeting a tough indication or racing to a milestone, we help you reach inflection points with clarity and confidence. Precision. Partnerships. Progress. That’s the Isogenica difference.
Trusted by Leading Biotech Innovators
From emerging biotechs to established pharma leaders, our partners rely on our speed, scale, and science
What You Can Expect from Isogenica

Faster Discovery, Stronger Candidates

CIS Display™ + Synthetic Scale

Built for Scientists. Backed by Cambridge.
Driven by Discovery. Trusted for Results.
VHH Resources
Explore our VHH resources – including white papers, blog posts and webinars

A Competitive and Ethical Future in Discovery
Traditionally, antibody generation relied on immunizing animals (e.g. mice, rabbits, or even llamas) to raise binders against a target antigen. However, emerging synthetic antibody library technologies now allow scientists to bypass animal immunization by using in silico designed vast libraries of human or humanized antibody fragments.
Upcoming Events
Check out our upcoming events and see where we’ve been recently.

Join us at On Helix 2025 on July 3rd, 2025
Connect with Isogenica at AET Basel June 10-12 2025
Latest News
Check out our latest news on collaborations and press releases

Cerberus Therapeutics Enters into Antibody Discovery Agreement with Isogenica to Advance Immune-Modulating Therapies
Strategic collaboration offering a transformative approach to synthetic VHH and peptide discovery integrating early-stage drug development.
Explore the science behind our antibody discovery platforms
White Paper “Data-Driven Validation of Synthetic VHHs”

Extending half-lives of VHH antibodies

Advantages of VHH in bi-specifics

Optimizing CAR-T and T-cell antibody engagers: a role for VHH single domain antibodies

Isogenica’s PD-L1 VHH as Functional Antagonists

Anti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth
